Arcus Biosciences Inc (RCUS)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 43.41% | 44.11% | 40.49% | 38.82% | -4.27% | -0.02% | 4.59% | 4.61% | 4.52% | 76.42% | 77.45% | 79.17% | 81.33% | 6.57% | 58.82% | 57.79% | 60.71% | 60.84% | -85.60% | -54.13% |
| Operating profit margin | -127.91% | -120.91% | -118.62% | -113.92% | -290.60% | -270.62% | -258.17% | -251.27% | -250.00% | 17.32% | 16.36% | 14.97% | 13.56% | -523.15% | -183.75% | -181.14% | -159.96% | -115.39% | -763.67% | -655.57% |
| Pretax margin | -109.30% | -102.28% | -99.60% | -95.78% | -257.26% | -241.30% | -234.25% | -232.78% | -237.50% | 19.06% | 17.02% | 15.18% | 13.81% | -522.39% | -183.27% | -180.44% | -158.49% | -112.63% | -745.18% | -631.95% |
| Net profit margin | -109.69% | -102.66% | -100.81% | -97.47% | -262.39% | -245.49% | -236.73% | -234.46% | -238.39% | 18.36% | 16.29% | 14.43% | 13.31% | -522.39% | -183.27% | -180.44% | -158.49% | -112.63% | -745.18% | -631.95% |
Arcus Biosciences Inc has shown varying trends in its profitability ratios over the reported periods. The Gross Profit Margin fluctuated significantly from negative values in early 2020 and 2022 to positive percentages in later quarters of 2020 and 2021. From 2022 onwards, the company maintained a positive Gross Profit Margin, showing improved efficiency in generating revenue after covering the cost of goods sold.
The Operating Profit Margin reflects a similar pattern, with the company sustaining negative margins in the beginning but gradually turning positive in December 2021. However, there were fluctuations in subsequent periods, indicating potential challenges in managing operating expenses efficiently.
The Pretax Margin and Net Profit Margin also exhibit a similar pattern, with consistent negative margins initially, followed by a positive turn in December 2021. The company showed improvement in profitability metrics in 2022, with positive margins reported. However, there was a reversal to negative margins in later periods, suggesting potential operational or financial issues impacting the bottom line.
Overall, Arcus Biosciences Inc's profitability ratios show a mix of positive and negative trends, highlighting the need for sustained efforts to enhance operational efficiency and maintain profitability in the long term.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -28.70% | -25.40% | -24.70% | -20.88% | -31.05% | -27.12% | -25.66% | -23.84% | -20.82% | 5.38% | 4.53% | 3.87% | 3.39% | -33.22% | -22.15% | -18.00% | -16.06% | -11.07% | -23.80% | -55.83% |
| Return on assets (ROA) | -24.61% | -21.57% | -20.99% | -17.87% | -28.04% | -24.60% | -23.52% | -22.25% | -19.85% | 5.71% | 4.51% | 3.73% | 3.33% | -33.17% | -22.10% | -17.93% | -15.91% | -10.80% | -23.22% | -53.82% |
| Return on total capital | -68.04% | -56.28% | -46.14% | -38.19% | -73.59% | -62.12% | -55.30% | -49.83% | -42.62% | 10.73% | 8.95% | 7.50% | 6.41% | -51.38% | -32.93% | -25.32% | -24.70% | -16.49% | -26.72% | -69.92% |
| Return on equity (ROE) | -58.35% | -47.79% | -39.21% | -32.67% | -66.45% | -56.35% | -50.71% | -46.50% | -40.64% | 11.38% | 8.91% | 7.23% | 6.29% | -51.31% | -32.85% | -25.23% | -24.47% | -16.09% | -26.07% | -67.40% |
Arcus Biosciences Inc's profitability ratios have shown a fluctuating trend over the analyzed period. The Operating Return on Assets (ROA) has improved from negative percentages in the range of -55.83% to -31.05% by the end of December 2023 but worsened slightly by the end of June 2024 to -24.70%. Similarly, the Return on Assets (ROA) and Return on Total Capital followed a similar pattern with improvements observed up to the end of June 2022, before deteriorating again by the end of June 2024. Return on Equity (ROE) also demonstrated a recovery after negative values, turning positive as of December 2021 and consistently improving until September 2022. However, by December 2024, ROE decreased to negative levels again. Overall, the company's profitability ratios indicate variability in performance over the analyzed period, with some signs of improvement in certain periods but also continued challenges in maintaining profitability.